



ESCII/NIBIT Meeting 2011

New Perspectives in the Immunotherapy of Cancer

Siena – Italy, October 19 - 22, 2011

Program Committee: GIORGIO PARMIANI (I, CO-CHAIR), MICHAIL PAPAMICHAIL (GR, CO-CHAIR), GUIDO FORNI (I), CHRISTOF HUBER (D), ROLF KIESSLING (SE), MICHELE MAIO (I), GIUSEPPE MASUCCI (SE), L ZITVOGEL (F)

Tentative preliminary Program:

1. ***A new look at the tumor-associated antigens (TAA) of clinical significance***
(Wednesday afternoon, October 19, 2:30-5:30 pm)

1.1 14.30 Welcomes

1.2 15.00 **Keynote Lecture: Tobias Sjöblom** (Uppsala). Tumor cell somatic mutations. A new source of tumor antigen

1.3 15.20 **Ugurs Sahin** (Mainz). RNA antigens and cancer vaccines

Coffee Break

1.4 15.40 **Luca Sigalotti** (Aviano). Epigenetic modulation of tumor antigens

1.5 16.00 **Giorgio Parmiani** (Milan). Peptide tumor antigens: advantages and disadvantages of their clinical use

1.6 16.20 *Four Selected oral presentations*

2. ***The microenvironment manipulation for improving the outcome of cancer immunotherapy*** (Thursday morning, October 20, 9:00 am-1:00 pm)

2.1 9.00 **Keynote Lecture: Thomas Gajewski** (Chicago). Interplay of immune effector and tumor cells in the lymph nodes of cancer patients

2.2 9.30 **Maria Pia Protti** (Milan). Th2-type inflammation in pancreatic cancer: role in disease progression and mechanisms of induction

2.3 9.50 **Jerome Galon** (Paris). Effector T cells and prognosis

Coffee Break

2.4 10.30 **Bernard Fox** (Portland). **Title TBD**

2.5 10.50 **Mario Colombo** (Milan). The extracellular matrix protein SPARC in cancer and immunity

2.6 11.10 **Maria Rescigno** (IEO, Milan): Salmonella-mediated therapy of tumors

2.7 11.30 *Four selected oral presentations*

LIGHT LUNCH

3. **TAA presentation by dendritic cells and its manipulation**

(Thursday afternoon, October 20, 2:00-4:00 pm)

- 3.1 14.00 **Keynote Lecture: Carl G. Figdor** (Nijmegen). Plasticity of DC and its exploitation for cancer therapy
- 3.2 14.30 **Vincenzo Russo** (Milan). LXR agonists and antitumor responses
- 3.3 14.50 **Ignacio Melero** (Pamplona) Cytokine modulation and dendritic cells
- 3.4 15.10 **Gerold Schuler** (Erlangen). DC-based vaccination: Clinical trials

Coffee Break

4. **Effectors of anti-tumor immunity** (Thursday afternoon, 4:00-6:00 pm)

Chairman: Lorenzo Moretta (Genoa)

- 4.1 16.00 **Keynote Lecture: Pierre G. Coulie** (Brussels). Role of T cells
- 4.2 16.30 **Rolf Kiessling** (Stochkolm). Overcoming hurdles in developing genetic vaccination against cancer
- 4.3 16.50 **Lorenzo Moretta** (Genoa). Human NK cells: their role in the therapy of high risk leukemias
- 4.4 17.10 **Paolo Dellabona** (Milan). The CD1/T cell axis in tumor immunosurveillance
- 4.5 **XXX (US) Title TBD**

Ore 19 ASSEMBLEA SOCI NIBIT

5. **Clinical studies of cancer vaccination** (Friday October 21, morning; 8.30-11.00 am)

- 5.1 8.30 **Keynote Lecture. Pedro Romero** (Lausanne). A new generation of cancer vaccine trials
- 5.2 9.00 **Hans-Georg Rammensee** (Tubingen):Peptide antigen characterization for clinical immunotherapy studies
- 5.3 9.20 **Massimo Di Nicola** (Milan). Serological identification of novel lymphoma associated antigens as candidate biotargets for immunotherapy
- 5.4 9.40 **Ulrich Keilholz** (Berlin). Vaccination targeting WT-1: from leukemia to solid tumors

Coffee Break

10.15 **George E. Peoples** (Houston). **Breast Cancer Vaccines**

- 5.5 10.35 **Vincent Brichard** (GSK, Brussels). MAGE vaccination in solid tumors

6. **Adoptive immunotherapy. Where are we** (Friday morning, October 21, 11:00 am-1:00 pm)

- 6.1 11.00 **Keynote Lecture. Chiara Bonini** (Milan). Adoptive immune therapy with TCR modified T cells in haematological tumors
- 6.2 11.30 **Nathalie Labarrière** (Nantes)
- 6.3 11.50 **Robert E. Hawkins** (Manchester). Adoptive immunotherapy with engineered T cells to targeted to CEA or CD19
- 6.4 12.10 **Jacob Schachter** (ISRAEL) Adoptive immunotherapy of advanced melanoma – The Sheba Experience
- 6.5 12.30 **Two selected oral presentations**

LIGHT LUNCH

7. **Why immunotherapy may not work** (Friday afternoon , October 21, 2:00-6:00 pm)
- 7.1 14.00 **Keynote Lecture. Dmitry I. Gabrilovich** (Tampa, US) Can the antitumor effect of cancer immunotherapy be improved by pharmacological regulation of tumor microenvironment
- 7.2 14.30 **Federico Garrido** (Granada). The immune escape of cancer: MHC expression and tumor rejection
- 7.3 14.50 **Paolo Antonio Ascierto** (Napoli). Overcoming Tregs barrier
- 7.4 15.10 **Vincenzo Bronte** (Verona). MDSC and their mechanism of suppression

Coffee Break

- 7.5 15.30 **Licia Rivoltini** (Milan). **Title To be defined.**
- 7.6 15.50 **Cristina Maccalli** (Milan). Immunomodulation of T cell-mediated activity by cancer stem cells
- 7.7 16.10 **Chiara Castelli** (Milan). Modulation of immunosuppressive cells during vaccination

8. **Combination biological therapy** (Saturday morning ; October 22; 8:30-11:00 am)
- 8.1 8.30 **Keynote lecture. Laurence Zitvogel** (Paris). Modulation of antitumor immunity by chemotherapy
- 8.2 9.00 **Matteo Bellone**, (Milan) Targeting the tumor MICROenVIRONMENT to increase the efficacy of immunotherapy
- 8.3 9.20 **Per thor Straten** (Copenhagen). CD8 T cells in Cancer, Killers, Suppressers and Supporters
- 8.4 9.40 **Paola Nisticò/Enrico Proietti** (Rome). Combination of chemotherapy and immunotherapy in melanoma
- 8.5 10.00 **Michele Maio** (Siena). Chemotherapy and anti-CTLA4 therapy in cancer

Coffee Break

9. Round table: (Saturday morning; October 22, h 11.00-1:30 pm). *The tumor immunotherapy network of European networks and the role of European tumor immunology community in promoting the science of Tumor Immunology/Immunotherapy.*

11-11:30 *Keynote lecture.* 11.00 Alex M.M. Eggermont (Paris – EATI). prospects and future of immunotherapy in Europe

Participants:

1) National European Networks.

Christof Huber (CIMT),
Michael Papamichail (ESCII)
Guido Forni (Torino)
Giuseppe Masucci (NCEV)
H. Mellstedt (CANVAS)

2) Industry representatives :

BMS, Axel Hoos ; Sigma Tau
Roberto Camerini,

3) European Community Projects:

Claudio Bordignon (European Programs)
Filippo Belardelli, Rome (EATRIS, ECRIN)
Maria Cristina Galli (EMEA)

LIGHT LUNCH